Cardiovascular and thromboembolic diseases are among the leading causes of death and disability, accounting for nearly 1 million deaths in the US annually1,2
In thromboembolic diseases, current treatments targeting the coagulation cascade can leave significant unmet need, with potential bleeding risk contributing to gaps in protection that may make patients vulnerable to a thromboembolic event.3
Unmet Need
Cardiovascular and thromboembolic diseases can be severe, and current management strategies do not fully address disease burden.
Treatment Landscape
Current therapies for thromboembolic diseases have demonstrated clinical benefits, but unmet needs remain.
Factor XIa Pathway
Current research is focused on uncovering potential new targets to help address current unmet needs.
References
- Wendelboe AM, Raskob GE. Global burden of thrombosis: epidemiologic aspects. Circ Res. 2016;118(9):1340-1347. doi:10.1161/CIRCRESAHA.115.306841
- Martin SS, Aday AW, Allen NB, et al. 2025 heart disease and stroke statistics: a report of US and global data from the American Heart Association. Circulation. 2025;151(8):e41-e660. doi: 10.1161/CIR.0000000000001303
- Fredenburgh JC, Weitz JI. Factor XI as a target for new anticoagulants. Hamostaseologie. 2021;41(2):104-110. doi:10.1055/a-1384-3715